Skip to main navigation Skip to search Skip to main content

An Open-Label Study to Evaluate the Effectiveness and safety of Ocrelizumab in Patients with Relapsing Remintting Mulitple Sclerosis who have had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment

Project: Research

Project Details

StatusFinished
Effective start/end date09/8/16 → 09/30/20

Funding

  • Genentech Incorporated: $94,667.38